^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Peritoneal Cancer
    Drug:Zejula (niraparib) (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Scottish Medicines Consortium
    Title:

    Niraparib (Zejula) is accepted for use within NHSScotland

    Published date:
    04/09/2021
    Excerpt:
    Niraparib (Zejula) is accepted for use within NHSScotland...as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III or IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated:...for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Zejula is indicated:...as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

    Published date:
    02/17/2021
    Excerpt:
    Niraparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
    Secondary therapy:
    Chemotherapy
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Acceptable Recurrence Therapies for…Peritoneal Cancer: Targeted Therapy...Niraparib